FluoroPharma Inc.

FluoroPharma Inc. of Boston, a developer of molecular imaging agents for the PET market, has announced successful Phase I safety results for BFPET, a fluorine-18-labeled tracer for myocardial perfusion imaging. The imaging agent analyzes blood flow in the heart and assesses coronary artery disease in patients.





LATEST NEWS

• AmeriCOM Adds President and CEO: People in the News: 5/1/24
  May 1, 2024
• Machine Learning Pushes High-Power Lasing Limits
  May 1, 2024
• IPG Names Industry Veteran Mark Gitin CEO
  Apr 30, 2024
• 16th Biannual Optatec Conference Continues in Frankfurt
  Apr 30, 2024
• Celestial Surface Mapping Tech Combines Established Techniques
  Apr 30, 2024
• TSMC Partnerships Target Integrated Photonics Capabilities
  Apr 30, 2024
• CLEO Heads to the East Coast
  Apr 29, 2024
• Qubits Could be Stored in Flash-Like Memory
  Apr 29, 2024